Sentence examples for mouse leukemia model from inspiring English sources

Furthermore, we showed that graft-versus-leukemia (GVL) effect against EL4/DsRed leukemic cells was maximally preserved while GVHD was minimized during exposure to engineered Tregs in a mouse leukemia model.

In a preclinical study using the L1210 mouse leukemia model, the curative dose of 5-AZA-CdR administered as a 15-hour infusion was 20 mg/kg.

A combination of genetic and pharmacological approaches using mouse leukemia models show that STAT5 phosphorylation is one of the major drivers of the proliferation of Philadelphia chromosome positive (BCR-ABL-positive or Ph+) chronic myeloid leukemia.

This approach yielded compounds such as (E -N-[6- hydroxyamino -6-oxohexyl]-3- 7-quinolinyl -2-propenamide (27) (HDAC IC50 8 nM) which showE -N-[6- hydroxyamino -6-oxohexyl]-3- 7-quinolinyl -2-propenamideodE -N-[6- hydroxyamino -6-oxohexyl]-3- 7-quinolinyl -2-propenamide

In vivo, the tumor growth inhibition caused by AT-101 was also associated with RhoA/ROCK1/PTEN activation and Akt inactivation in a mouse leukemia xenograft model.

Our in vivo study also showed that AITC-mediated inhibition of tumor growth of mouse leukemia xenograft model is in association with dephosphorylation of cofilin.

Our in vivo study also showed that UA-mediated inhibition of tumor growth of mouse leukemia xenograft model is in association with the dephosphorylation/downregulation of ezrin.

Our in vivo study showed that both ROCK1 activation and MLC phosphorylation were associated with the tumor growth inhibition caused by triptolide in mouse leukemia xenograft models.

Our previous studies employed lentivector-mediated expression of murine IL-12 in tumor cells and demonstrated effective protection in both mouse leukemia and solid tumor challenge models.

Generation of the Eμ-Myc B-cell leukemia model in mice with heterozygosity in the gene encoding the L24 ribosomal protein restored normal levels of protein synthesis in the leukemic cells, thereby suppressing Myc's oncogenic potential [ 39].

In this regard, it is interesting to note that our data on cytosine arabinoside (cytarabine, ARA-C) in the L1210 leukemia model in mice [ 31] shows a good correlation with clinical studies on intensive dose ARA-C in patients with acute myeloid leukemia [ 32].